Nine important updates for World Thrombosis Day
Click Here to Manage Email Alerts
World Thrombosis Day is observed Oct. 13.
The campaign is intended to raise awareness of the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.
In conjunction with this observance, Healio presents the following important updates in thrombosis treatment, surveillance and risk prediction.
Patients hospitalized with COVID-19 remain at higher risk for thromboembolic events and death after discharge than previously thought. Read more.
The REGARDS study, which included a contemporary cohort of people in the United States, showed no evidence of interaction among TV viewing, physical activity and venous thromboembolism risk. Read more.
A single IV dose of the factor XI monoclonal antibody abelacimab (Anthos Therapeutics) appeared superior to daily enoxaparin for preventing VTE after total knee arthroplasty. Read more.
The FDA approved dabigatran etexilate (Pradaxa, Boehringer Ingelheim) oral pellets for children aged 3 months to 11 years with VTE who already received a blood thinner by injection for at least 5 days. The agency also approved the therapy to prevent clots among children in the same age range who completed treatment for their first VTE. Read more.
Patients with cancer appeared at increased risk for arterial thromboembolism and mortality within 1 year of cancer diagnosis compared with the general population. Read more.
Gender‐affirming hormone therapy appeared to increase overall procoagulant profiles among transgender women but not transgender men. Read more.
Patients hospitalized with severe and non-severe COVID-19 appeared at increased risk for symptomatic VTE. Read more.
Patients with anaplastic lymphoma kinase-mutant non-small cell lung cancer exhibited considerably higher risk for thromboembolism than those with EGFR-mutant or wild-type disease. Read more.
Patients who continued to use anticoagulant therapy beyond the initial 3 to 6 months of treatment for a first unprovoked VTE demonstrated considerable bleeding risk. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts